NEW BRUNSWICK, N.J. / Aug 07, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the 2023 Wells Fargo Securities Healthcare Conference at the Encore Boston Harbor in Everett, MA on Thursday, September 7th. Ashley McEvoy, EVP, Worldwide Chairman, MedTech along with executives from Abiomed will represent the Company in a session scheduled at 10:15 a.m. (Eastern Time).
This conference call will be available to investors and other interested parties by visiting the Johnson & Johnson website at www.investor.jnj.com.
A webcast and podcast replay will be available approximately 48 hours after the live webcast.
| Last Trade: | US$153.63 |
| Daily Change: | -2.15 -1.38 |
| Daily Volume: | 1,259,964 |
| Market Cap: | US$370.250B |
November 22, 2024 November 19, 2024 November 14, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
